[go: up one dir, main page]

ES2116471T3 - Arilcarbonil y alcoxicarbonil carbamatos de rapamicina como agentes inmunosupresores y antifungicos. - Google Patents

Arilcarbonil y alcoxicarbonil carbamatos de rapamicina como agentes inmunosupresores y antifungicos.

Info

Publication number
ES2116471T3
ES2116471T3 ES93923284T ES93923284T ES2116471T3 ES 2116471 T3 ES2116471 T3 ES 2116471T3 ES 93923284 T ES93923284 T ES 93923284T ES 93923284 T ES93923284 T ES 93923284T ES 2116471 T3 ES2116471 T3 ES 2116471T3
Authority
ES
Spain
Prior art keywords
carbamates
image
arilcarbonil
alcoxicarbonil
rapamicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93923284T
Other languages
English (en)
Inventor
Wenling Kao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2116471T3 publication Critical patent/ES2116471T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

CARBAMATOS DE N-ARILCARBONILO Y N-ALQUILCARBONILO DE RAPAMICINA DE LA FORMULA (I) EN LA QUE R1 ES (A) Y R2 ES H O (B) O R1 Y R2 SON LOS DOS (A) Y DONDE A ES ALCOXI INFERIOR O ARILO O HETEROARILO, R3 ES H O METILO Y R4 ES ALQUILO C1-C6, ALQUENILO C2-C6 O ALQUINILO C2-C6 QUE POSEEN UNA ACTIVIDAD INMUNOSUPRESORA Y/O FUNGICIDA Y/O ANTITUMORAL Y/O ANTIINFLAMATORIA IN VITRO Y/O INHIBEN LA PROLIFERACION DE TIMOCITOS IN VIVO. ESTOS COMPUESTOS SON POR TANTO UTILES PARA EL TRATAMIENTO DEL RECHAZO A TRANSPLANTES, DE ENFERMEDADES AUTOINMUNES, INFECCIONES FUNGICAS, EL CANCER Y ENFERMEDADES INFLAMATORIAS.
ES93923284T 1992-10-29 1993-10-06 Arilcarbonil y alcoxicarbonil carbamatos de rapamicina como agentes inmunosupresores y antifungicos. Expired - Lifetime ES2116471T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/968,115 US5262423A (en) 1992-10-29 1992-10-29 Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents

Publications (1)

Publication Number Publication Date
ES2116471T3 true ES2116471T3 (es) 1998-07-16

Family

ID=25513757

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93923284T Expired - Lifetime ES2116471T3 (es) 1992-10-29 1993-10-06 Arilcarbonil y alcoxicarbonil carbamatos de rapamicina como agentes inmunosupresores y antifungicos.

Country Status (12)

Country Link
US (1) US5262423A (es)
EP (1) EP0666861B1 (es)
JP (1) JPH08502748A (es)
AT (1) ATE166653T1 (es)
AU (1) AU5322294A (es)
CA (1) CA2148247A1 (es)
DE (1) DE69318846T2 (es)
DK (1) DK0666861T3 (es)
ES (1) ES2116471T3 (es)
MX (1) MX9306730A (es)
TW (1) TW239136B (es)
WO (1) WO1994010176A1 (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
JP4105761B2 (ja) * 1993-11-19 2008-06-25 アボット・ラボラトリーズ ラパミシン（マクロライド）の半合成類似体免疫調節剤
SG64372A1 (en) * 1993-12-17 1999-04-27 Novartis Ag Rapamycin derivatives
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
AU712193B2 (en) * 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
CN100448487C (zh) 2000-08-11 2009-01-07 惠氏公司 治疗雌激素受体阳性癌的方法
DE60136200D1 (de) 2000-09-19 2008-11-27 Wyeth Corp Wasserlösliche rapamycin-ester
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2493878C (en) 2002-07-30 2013-07-23 Wyeth Parenteral formulations containing a rapamycin hydroxyester
WO2004060283A2 (en) 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
CA2562962A1 (en) * 2004-04-14 2005-11-10 Wyeth Process for preparing rapamycin 42-esters and fk-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
BRPI0510277A (pt) * 2004-04-27 2007-10-30 Wyeth Corp método para marcar especificamente uma rapamicina, rapamicina especificamente marcada, composição, e, kit
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
AU2005302004A1 (en) * 2004-10-28 2006-05-11 Wyeth Use of an mTOR inhibitor in treatment of uterine leiomyoma
ES2663495T3 (es) * 2005-02-18 2018-04-13 Abraxis Bioscience, Llc Fármacos con hidrofobicidad mejorada para incorporación en dispositivos médicos
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
US20080051691A1 (en) * 2006-08-28 2008-02-28 Wyeth Implantable shunt or catheter enabling gradual delivery of therapeutic agents
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20100048914A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
AU2009234277B2 (en) 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2365802B1 (en) 2008-11-11 2017-08-02 The Board of Regents,The University of Texas System Microcapsules of rapamycin and use for treating cancer
EP3023433A1 (en) 2009-02-05 2016-05-25 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US20120316137A1 (en) 2009-10-30 2012-12-13 Ariad Pharmaceuticals, Inc. Methods and Compositions for Treating Cancer
US20170079962A1 (en) 2009-11-11 2017-03-23 Rapamycin Holdings, Llc Oral Rapamycin Preparation and Use for Stomatitus
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2011109833A2 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
RU2585489C2 (ru) 2010-04-27 2016-05-27 Рош Гликарт Аг КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
WO2014059295A1 (en) 2012-10-12 2014-04-17 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
EP2914260A1 (en) 2012-10-31 2015-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
WO2015149001A1 (en) 2014-03-27 2015-10-01 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
MX2016015569A (es) 2014-06-02 2017-04-25 Children´S Medical Center Corp Metodos y composiciones para inmunomodulacion.
WO2016040806A1 (en) 2014-09-11 2016-03-17 The Regents Of The University Of California mTORC1 INHIBITORS
WO2016205334A1 (en) 2015-06-16 2016-12-22 Vascular Strategies Llc Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
EP3624863B1 (en) 2017-05-15 2021-04-14 C.R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
US20200129486A1 (en) 2017-06-26 2020-04-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of olmsted syndrome
WO2019012024A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS FOR INCREASING EXPANSION AND IMMUNOSUPPRESSIVE CAPACITY OF A CD8 + CD45RCBAS TREGS POPULATION / -
CA3098692A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
WO2019212991A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
EP3826649A4 (en) 2018-07-23 2022-07-20 Enclear Therapies, Inc. Methods of treating neurological disorders
EP3826650A4 (en) 2018-07-23 2022-07-27 Enclear Therapies, Inc. METHODS OF TREATMENT OF NEUROLOGICAL DISEASES
EP3849545A1 (en) 2018-09-10 2021-07-21 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of neurofibromatosis
JP7262581B2 (ja) 2018-11-14 2023-04-21 ルトニックス，インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
JP7487228B2 (ja) 2019-04-08 2024-05-20 バード・ペリフェラル・バスキュラー・インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
JP2022526671A (ja) 2019-04-11 2022-05-25 エンクリアー セラピーズ， インク． 脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム
WO2022072558A1 (en) 2020-09-29 2022-04-07 Enclear Therapies, Inc. Subarachnoid fluid management method and system
WO2023288046A1 (en) 2021-07-15 2023-01-19 President And Fellows Of Harvard College Compositions and methods relating to cells with adhered particles
AU2023275778A1 (en) 2022-05-25 2024-12-12 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor
CN115160343B (zh) * 2022-06-09 2023-11-14 福建省微生物研究所 一种雷帕霉素衍生物及其制备方法和应用
WO2024008799A1 (en) 2022-07-06 2024-01-11 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of proliferative glomerulonephritis
WO2024028433A1 (en) 2022-08-04 2024-02-08 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JPH05504956A (ja) * 1990-03-12 1993-07-29 藤沢薬品工業株式会社 トリシクロ化合物
PT98990A (pt) * 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin

Also Published As

Publication number Publication date
DE69318846D1 (en) 1998-07-02
DE69318846T2 (de) 1999-01-28
US5262423A (en) 1993-11-16
ATE166653T1 (de) 1998-06-15
MX9306730A (es) 1994-06-30
EP0666861A1 (en) 1995-08-16
WO1994010176A1 (en) 1994-05-11
JPH08502748A (ja) 1996-03-26
EP0666861B1 (en) 1998-05-27
TW239136B (es) 1995-01-21
AU5322294A (en) 1994-05-24
CA2148247A1 (en) 1994-05-11
DK0666861T3 (da) 1998-11-09

Similar Documents

Publication Publication Date Title
ES2116471T3 (es) Arilcarbonil y alcoxicarbonil carbamatos de rapamicina como agentes inmunosupresores y antifungicos.
ES2179049T3 (es) Oxepano-isomeros de rapamicina utiles como agentes inmunosupresores.
CA2117059A1 (en) Pyrido-pyridazinone and pyridazinthione compounds
MY131013A (en) Aryl derivatives
DE69419032D1 (de) Gehinderte ester von rapamycin und ihre verwendung als arzneimittel
TR200003061T2 (tr) Kinolin türevleri
FI972240A0 (fi) Rapamysiinin estetyt N-oksidiesterit ja niiden käyttö lääkkeinä
BG104316A (en) Tetrazolecontaining analogues of rapamycin, having reduced period of semidecomposition
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
NZ510435A (en) Arylsulfonanilide ureas and pharmaceutical use
WO2005092858A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
ES2083526T3 (es) Derivados piranicos biciclicos y su uso como inhibidores de 5-lipoxigenasa.
ES2177583T3 (es) Nuevo compuesto tetraciclico.
RU2008127257A (ru) Тризамещенные производные хиназолинона в качестве ваниллоидных антагонистов
PT652874E (pt) 2-heterociclico-5-hidroxi-1,3-pirimidinas uteis como agentes anti-inflamatorios
DE60101739D1 (de) Makrolide
AR017997A3 (es) Procedimiento para preparar compuestos aza ciclohexapeptidos y compuestos para su exclusivo uso en dicho procedimiento
AU554959B2 (en) Triazolo(4,3-a) quinazolin-5-ones
BR9707250A (pt) Dihidrobenzofurano e compostos correlatos úteis como agentes antiinflamatórios
DE60031699D1 (de) Hydroxyacetamidobenzolsulfonamidderivate
ATE303398T1 (de) Selektive glucocorticoid rezeptor agonisten
ATE271052T1 (de) Wasserlösliche sdz-rad ester
DE60028563D1 (de) Aryl-chloralkyl harnstoffe
CA2228393A1 (en) Use of adamantane derivatives for treating diseases of the inner ear

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 666861

Country of ref document: ES